IKT on Nasdaq

Inhibikase Therapeutics, Inc.

American biological products company based in Atlanta, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Artiva Biotherapeutics, Inc., CytRx or PALISADE BIO, INC., or pick any stock.

  • TickerIKT on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersAtlanta, United States2
  • Incorporated inDE3
  • Business address1000 N. West Street, Suite 1200, Wilmington, De 198013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300066CFEWOA17F122
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 48322442

See how the biggest companies compare on our leaderboards

We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit”, has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approxim…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-100.0%Revenue growth, 20245
-29.0%Return on equity6
-$19.1MFree cash flow6

Financial statements

Revenue7895$0 in 2024
0$1.0M$2.0M$3.0M$4.0M2020: $698.5K$698.5K20202021: $3.1M$3.1M2021+344%2022: $123.4K$123.4K2022−96%2023: $260.5K$260.5K2023+111%2024: $0$02024
Operating income78956-$28.6M in 2024+914% since 2020
-$30.0M-$20.0M-$10.0M02020: -$2.8M-$2.8M20202021: -$14.8M-$14.8M2021+424%2022: -$18.1M-$18.1M2022+23%2023: -$20.1M-$20.1M2023+11%2024: -$28.6M-$28.6M2024+42%
Net income78956-$27.5M in 2024+866% since 2020
-$30.0M-$20.0M-$10.0M02020: -$2.8M-$2.8M20202021: -$14.8M-$14.8M2021+419%2022: -$18.1M-$18.1M2022+22%2023: -$19.0M-$19.0M2023+5%2024: -$27.5M-$27.5M2024+45%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development$29.8M$17.2M
Selling, general and administrative$23.6M$11.4M
Change in fair value contingent consideration-$1.4M$0
Total costs and expenses$52.0M$28.6M
Loss from operations-$52.0M-$28.6M
Interest income$3.7M$1.1M
Net loss-$48.3M-$27.5M
Unrealized gain (loss) on marketable securities$59.0K-$38.1K
Comprehensive loss-$48.2M-$27.6M
Net loss per share - basic-$0.49-$1.16
Net loss per share - diluted-$0.49-$1.16
Weighted-average number of shares_basic98.3M shares23.7M shares
Weighted-average number of shares_diluted98.3M shares23.7M shares

Compare Inhibikase Therapeutics, Inc. with another company

Leadership

Who has led Inhibikase Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Milton H. Werner2020–2025
  2. Mark T. Iwicki2025–now

President

  1. Milton H. Werner2020–2025
  2. Christopher Cabell2025–now

Chief financial officer

  1. Joseph Frattaroli2020–2022
  2. Garth Lees-Rolfe2024–2025
  3. David McIntyre2025–now
2025
Board members and other officers (13)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorMilton H. Werner Ph.D named Feb 7, 202329

Timeline

  1. Feb 19, 2025New chief executive Mark T. Iwicki becomes CEO12
  2. Dec 22, 2020New chief executive Milton H. Werner becomes CEO13
  3. Jun 3, 2010Founded Inhibikase Therapeutics, Inc. is founded2

Filings

287 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 60 major events, 91 insider forms, 37 large holders, 2 private raises, 75 other. The latest 20:

  1. Sep 8, 20268-K EDGAR
  2. Aug 26, 20268-K EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 13, 2026SCHEDULE 13G/A EDGAR
  6. Aug 11, 2026S-8 EDGAR
  7. Aug 11, 202610-Q EDGAR
  8. Aug 11, 20268-K EDGAR
  9. Jul 31, 2026SCHEDULE 13G/A EDGAR
  10. Jul 31, 20264 EDGAR
  11. Jul 31, 20264 EDGAR
  12. Jul 29, 20268-K EDGAR
  13. Jul 28, 2026SCHEDULE 13G EDGAR
  14. Jul 23, 20268-K EDGAR
  15. Jul 17, 2026SCHEDULE 13G EDGAR
  16. Jul 17, 20263 EDGAR
  17. Jul 14, 20268-K EDGAR
  18. Jun 30, 20264 EDGAR
  19. Jun 30, 20264 EDGAR
  20. Jun 30, 20264 EDGAR

The 287 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 9 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 21, 2025SANDS FRANK M.10% ownerBuy2,068,965$1.45$3.0MForm 4
Oct 21, 2024Bellini RobertoDirectorBuy1,460,000$1.37$2.0MForm 4
Oct 21, 2024Kush ArvindDirectorBuy145,000$1.37$198.7KForm 4
Oct 21, 2024Munshi AmitDirectorBuy365,000$1.37$500.1KForm 4
Aug 16, 2022Werner Milton H.President and CEOBuy5,000$0.80$4.0KForm 4
May 27, 2022Werner Milton H.President and CEOBuy5,000$0.98$4.9KForm 4
May 20, 2022Werner Milton H.President and CEOBuy10,000$0.60$6.0KForm 4
May 19, 2022FRATTAROLI JOSEPHCheif Financial OfficerBuy3,948$0.64$2.5KForm 4
Nov 17, 2021Werner Milton H.President and CEOBuy23,589$1.97$46.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 20, 2024Filed a private offering of equity Form D: $8 million offered in all Form D
  2. Jan 27, 2023Raised $4.2 million in a private offering of securities Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Sands Capital Alternatives, LLC13,018,965$26.4M4.3%No change
Soleus Capital Management, L.P.10,875,000$22.1M0.8%No change
Trails Edge Capital Partners, LP9,051,318$18.4M2.9%+993,973
Fairmount Funds Management LLC8,625,000$17.5M1.2%No change
BlackRock, Inc.7,768,057$15.8M0.0%+1,464,624
Kalehua Capital Management LLC7,643,780$15.5M4.9%+1,149,282
ADAR1 Capital Management, LLC7,387,205$15.0M0.7%+780,633
Blackstone Inc.5,938,276$12.1M0.0%No change
Siren, L.L.C.5,850,000$11.9M0.2%No change
Nantahala Capital Management, LLC5,403,726$11.0M0.3%+2,701,863
Commodore Capital LP5,397,488$11.0M0.7%No change
Vanguard Capital Management LLC4,935,354$10.0M0.0%+484,689
Millennium Management LLC4,028,102$8.2M0.0%+1,100,025
Saturn V Capital Management LP3,869,056$7.9M1.1%+5,611
Spruce Street Capital LP3,581,603$7.3M1.4%No change
Squadron Capital Management LLC3,000,000$6.1M2.1%−500,000
Geode Capital Management, LLC2,607,129$5.3M0.0%+436,943
State Street Corp1,909,101$3.9M0.0%+223,285
SummitTX Capital, L.P.1,780,262$3.6M0.1%+255,726
Integral Health Asset Management, LLC1,350,000$2.7M0.1%No change
Northern Trust Corp878,585$1.8M0.0%+159,785
Vanguard Portfolio Management LLC809,490$1.6M0.0%+191,760
Two Sigma Investments, LP806,264$1.6M0.0%−41,347
Sphera Funds Management Ltd.649,309$1.3M0.2%New
Vanguard Fiduciary Trust Co607,260$1.2M0.0%+40,261

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44